Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Supemtek

- PMLiVE

Sanofi/GSK vaccine boosts immune response

The vaccine boosted neutralising antibodies by 9 to 43-fold regardless of which vaccine was given as a primary course

- PMLiVE

Sanofi to buy acne specialist Origimm

The acquisition brings Origimm’s ORI-001 vaccine candidate against acne vulgaris into Sanofi’s vaccine pipeline, building its strength in mRNA technology

- PMLiVE

Sanofi sees double-digit growth driven by ‘megabrand’ Dupixent

With strong growth in specialty care, vaccines and consumer health seeing sales rise by 10% in the third quarter, Sanofi now expects earnings to grow by 14% in 2021

- PMLiVE

Real-world data highlights flu vaccine efficacy

Flu vaccinations prevented 7.5 million illnesses and 6,300 deaths from influenza in 2019/20

Sanofi reception

Sanofi’s tolebrutinib demonstrates favourable one-year tolerability in patients with relapsing forms of multiple sclerosis

New long-term data presented at ECTRIMS 2021 reinforces promising safety and efficacy profile

- PMLiVE

Sanofi refocuses COVID-19 efforts away from mRNA

Trial data validates Sanofi’s mRNA and lipid nanoparticle platform but the company will not pursue its own mRNA COVID-19 vaccine

- PMLiVE

Sanofi boosts transplant portfolio with newly approved Rezurock

Sanofi’s acquisition of Kadmon Holdings adds Rezurock to its transplant portfolio in a deal worth $1.9bn.

- PMLiVE

EC approves BMS cell therapy for multiple myeloma

The approval of Abecma is based on “rapid, deep and durable” trial responses

- PMLiVE

EMA begins rolling review of Sanofi, GSK’s COVID-19 vaccine

Rolling review launched based on preliminary results from lab studies and early clinical studies

- PMLiVE

Sanofi signs $1bn licence agreement for Eureka’s novel multiple myeloma drug

Multiple myeloma is the second most common blood cancer

- PMLiVE

AstraZeneca clears latest hurdle for Alexion acquisition after EU clearance

AZ first announced the proposed acquisition of Alexion in December 2020

- PMLiVE

EU identifies first five ‘promising’ COVID-19 drugs as part of therapeutics strategy

The five therapeutic candidates include a repurposed arthritis med and monoclonal antibodies

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links